THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVE

Thorir D. Bjornsson(Pfizer (United States)), John T. Callaghan, Heidi J. Einolf(Novartis (China)), Volker Fischer(Novartis (China)), Lawrence L. Gan(Takeda (Japan)), Scott Grimm(AstraZeneca (Brazil)), John Y. Kao(Pfizer (United States)), Shang‐Ying P. King, Gerald T. Miwa(Takeda (Japan)), Lan Ni, Gondi Kumar, James F. McLeod(Novartis (China)), R. Scott Obach(Pfizer (United States)), Stanley Roberts(Abbott (United Kingdom)), Amy L. Roe(Procter & Gamble (United States)), Anita Shah(Bayer (Germany)), Fred Snikeris(Sanofi (Mexico)), John T. Sullivan, Donald Tweedie, José M. Vega, John Walsh(GlaxoSmithKline (Netherlands)), Steven Wrighton
Drug Metabolism and Disposition
June 18, 2003
Cited by 784

Abstract


Related Papers

No related papers found

Powered by citation graph analysis